Protocol for screening potential targets for the treatment of hepatocellular carcinoma based on H22 tumor-bearing mouse model

Regulating cancer-related microRNAs (miRNAs) may become a new generation of therapeutic modalities for cancer treatment. Here, we describe a protocol based on hepatoma-22 (H22) tumor-bearing mice to screen potential targets for treating hepatocellular carcinoma (HCC). We detail the construction of H22 tumor-bearing mice and treatment with two natural compounds, Ulva lactuca L. polysaccharide (ULP) and 5-fluorouracil (5FU). We further describe the isolation of the tumor tissues for miRNA sequencing and the discovery and validation of potential miRNA gene targets against HCC. For complete details on the use and execution of this protocol, please refer to Qiu et al.1 [Display omitted] •Detailed steps for preparing H22 tumor-bearing mice•Instructions for detecting miRNA with significant change in H22 tumor-bearing mice•Guidance on the screen of natural compound in H22 tumor-bearing mice Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. Regulating cancer-related microRNAs (miRNAs) may become a new generation of therapeutic modalities for cancer treatment. Here, we describe a protocol based on hepatoma-22 (H22) tumor-bearing mice to screen potential targets for treating hepatocellular carcinoma (HCC). We detail the construction of H22 tumor-bearing mice and treatment with two natural compounds, Ulva lactuca L. polysaccharide (ULP) and 5-fluorouracil (5FU). We further describe the isolation of the tumor tissues for miRNA sequencing and the discovery and validation of potential miRNA gene targets against HCC.